Literature DB >> 10037197

Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma.

X X Tang1, G M Brodeur, B G Campling, N Ikegaki.   

Abstract

The EPH family is the largest subfamily of receptor protein tyrosine kinases, consisting of the EPHA and EPHB subgroups. Ephrin-B1, ephrin-B2, and ephrin-B3 are ligands of the EPHB subgroup and are encoded by the EFNB1, EFNB2, and EFNB3 genes, respectively. We have shown previously that EPHB2 transcripts are expressed in six small cell lung carcinoma (SCLC) cell lines. In this study, we examined the expression of EPHB1, EPHB2, EPHB3, EPHB4, and EPHB6 in 4 SCLC tumor specimens and 14 cell lines including 3 cell lines derived from these tumor specimens. To investigate whether potential autocrine loops of EPHB receptors and ephrin-B ligands exist in SCLC, the expression of EFNB1, EFNB2, and EFNB3 was also examined. Our data show that transcripts encoding multiple members of the EPHB subgroup and the ephrin-B subgroup are coexpressed in SCLC cell lines and tumors. These results suggest that the EPHB subgroup receptor kinases may modulate the biological behavior of SCLC through autocrine and/or juxtacrine activation by ephrin-B ligands that are expressed in the same or neighboring cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037197

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

1.  Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis.

Authors:  H Chaib; E K Cockrell; M A Rubin; J A Macoska
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

2.  The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway.

Authors:  Roy Barco; Laura B Hunt; Andrea L Frump; Christina B Garcia; Andrew Benesh; Robert L Caldwell; Josiane E Eid
Journal:  Mol Biol Cell       Date:  2007-08-08       Impact factor: 4.138

3.  Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.

Authors:  Yanyang Tu; Shiming He; Jianfang Fu; Gang Li; Ruxiang Xu; Hongliu Lu; Jianping Deng
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

4.  EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion.

Authors:  Mitsutoshi Nakada; Jared A Niska; Nhan L Tran; Wendy S McDonough; Michael E Berens
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 5.  EphB4: A promising target for upper aerodigestive malignancies.

Authors:  Ravi Salgia; Prakash Kulkarni; Prakash S Gill
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

6.  Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.

Authors:  Whitney A Spannuth; Lingegowda S Mangala; Rebecca L Stone; Amy R Carroll; Masato Nishimura; Mian M K Shahzad; Sun-Joo Lee; Myrthala Moreno-Smith; Alpa M Nick; Ren Liu; Nicholas B Jennings; Yvonne G Lin; William M Merritt; Robert L Coleman; Pablo E Vivas-Mejia; Yue Zhou; Valery Krasnoperov; Gabriel Lopez-Berestein; Parkash S Gill; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

7.  Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma.

Authors:  X X Tang; H Zhao; M E Robinson; B Cohen; A Cnaan; W London; S L Cohn; N K Cheung; G M Brodeur; A E Evans; N Ikegaki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

8.  A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.

Authors:  Theresa L Werner; Mark L Wade; Neeraj Agarwal; Kenneth Boucher; Jesal Patel; Aaron Luebke; Sunil Sharma
Journal:  Invest New Drugs       Date:  2015-09-14       Impact factor: 3.850

9.  Expression of Ephb2 and Ephb4 in breast carcinoma.

Authors:  Qinghua Wu; Zhenhe Suo; Bjørn Risberg; Mats G Karlsson; Kenneth Villman; Jahn M Nesland
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

10.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.